$XCUR
Exicure Inc

2018 Q1 Form 10-K Financial Statement

#000169853018000007 Filed on March 09, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 2016 Q4
Revenue $36.00K $9.719M $690.0K
YoY Change -98.52% 838.13%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.050M $7.050M $800.0K
YoY Change 43.36% 99.15%
% of Gross Profit
Research & Development $3.275M $13.08M $5.330M
YoY Change -6.11% -4.24%
% of Gross Profit
Depreciation & Amortization $90.00K $230.0K $50.00K
YoY Change 125.0% 27.78%
% of Gross Profit
Operating Expenses $5.320M $20.13M $6.130M
YoY Change 8.26% 17.03%
Operating Profit -$5.284M -$10.41M
YoY Change 112.89% -35.61%
Interest Expense $161.0K $795.0K -$210.0K
YoY Change -21.08% 9.81%
% of Operating Profit
Other Income/Expense, Net -$225.0K -$604.0K $10.00K
YoY Change 32.35% -22.46%
Pretax Income -$5.510M -$12.04M -$5.640M
YoY Change 107.92% -28.94%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.509M -$11.01M -$5.640M
YoY Change 107.73% -35.0%
Net Earnings / Revenue -15302.78% -113.29% -817.39%
Basic Earnings Per Share
Diluted Earnings Per Share -$140.0K -$306.4K -$143.5K
COMMON SHARES
Basic Shares Outstanding 39.45M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.10M $25.80M
YoY Change 31.63%
Cash & Equivalents $21.12M $25.80M $19.62M
Short-Term Investments
Other Short-Term Assets $1.900M $1.800M
YoY Change 350.0%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $23.05M $27.60M $20.04M
YoY Change 38.0%
LONG-TERM ASSETS
Property, Plant & Equipment $1.275M $1.300M $503.0K
YoY Change 160.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $32.00K $0.00 $32.00K
YoY Change
Total Long-Term Assets $1.307M $1.400M $535.0K
YoY Change 133.33%
TOTAL ASSETS
Total Short-Term Assets $23.05M $27.60M $20.04M
Total Long-Term Assets $1.307M $1.400M $535.0K
Total Assets $24.35M $29.00M $20.58M
YoY Change 40.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $974.0K $1.000M $509.0K
YoY Change 100.0%
Accrued Expenses $1.265M $1.300M $2.160M
YoY Change -40.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $776.0K $0.00 $1.213M
YoY Change -100.0%
Total Short-Term Liabilities $3.015M $3.400M $12.16M
YoY Change -72.13%
LONG-TERM LIABILITIES
Long-Term Debt $4.103M $4.900M $4.454M
YoY Change 4.26%
Other Long-Term Liabilities $277.0K $800.0K $281.0K
YoY Change -38.46%
Total Long-Term Liabilities $4.380M $5.700M $4.735M
YoY Change -5.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.015M $3.400M $12.16M
Total Long-Term Liabilities $4.380M $5.700M $4.735M
Total Liabilities $8.046M $9.000M $18.13M
YoY Change -50.28%
SHAREHOLDERS EQUITY
Retained Earnings -$38.09M -$22.60M
YoY Change
Common Stock $4.000K $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.31M $20.00M $2.448M
YoY Change
Total Liabilities & Shareholders Equity $24.35M $29.00M $20.58M
YoY Change 40.78%

Cashflow Statement

Concept 2018 Q1 2017 2016 Q4
OPERATING ACTIVITIES
Net Income -$5.509M -$11.01M -$5.640M
YoY Change 107.73% -35.0%
Depreciation, Depletion And Amortization $90.00K $230.0K $50.00K
YoY Change 125.0% 27.78%
Cash From Operating Activities -$4.647M -$19.79M $5.630M
YoY Change -33.59% 291.86%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $926.0K -$70.00K
YoY Change -100.0% 135.03%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$926.0K -$70.00K
YoY Change -100.0% 135.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $31.51M
YoY Change
Debt Paid & Issued, Net $1.001M
YoY Change
Cash From Financing Activities $7.000K $26.86M 10.00K
YoY Change -83.72% 323.86%
NET CHANGE
Cash From Operating Activities -$4.647M -$19.79M 5.630M
Cash From Investing Activities $0.00 -$926.0K -70.00K
Cash From Financing Activities $7.000K $26.86M 10.00K
Net Change In Cash -$4.640M $6.141M 5.570M
YoY Change -35.55% 588.45%
FREE CASH FLOW
Cash From Operating Activities -$4.647M -$19.79M $5.630M
Capital Expenditures $0.00 $926.0K -$70.00K
Free Cash Flow -$4.647M -$20.72M $5.700M
YoY Change -35.83% 280.51%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 dei Document Type
DocumentType
10-K
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001698530
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39454821 shares
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017Q2 dei Entity Public Float
EntityPublicFloat
0 USD
CY2017 dei Entity Registrant Name
EntityRegistrantName
EXICURE, INC.
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
509000 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1049000 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2160000 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1369000 USD
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
123000 USD
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
251000 USD
CY2012Q1 us-gaap Accrued Rent Current And Noncurrent
AccruedRentCurrentAndNoncurrent
52000 USD
CY2016Q4 us-gaap Accrued Rent Current And Noncurrent
AccruedRentCurrentAndNoncurrent
50000 USD
CY2017Q4 us-gaap Accrued Rent Current And Noncurrent
AccruedRentCurrentAndNoncurrent
48000 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
617000 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
849000 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
-17578000 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
53586000 USD
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
682000 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1462000 USD
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
682000 USD
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1462000 USD
CY2016 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
193000 USD
CY2017 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
189000 USD
CY2016Q4 us-gaap Assets
Assets
20576000 USD
CY2017Q4 us-gaap Assets
Assets
28055000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
20041000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
26706000 USD
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
11000 USD
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
120000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18731000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19623000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25764000 USD
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
892000 USD
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6141000 USD
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30782380 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131644 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39300823 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131644 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2017Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
4999000 USD
CY2017Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
129000 USD
CY2016 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
231000 USD
CY2017 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0 USD
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39300823 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
0 USD
CY2017Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
15000 USD
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2000 USD
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
8000 USD
CY2016Q4 us-gaap Deferred Revenue
DeferredRevenue
9310000 USD
CY2017Q4 us-gaap Deferred Revenue
DeferredRevenue
1034000 USD
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8276000 USD
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1034000 USD
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1034000 USD
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
0 USD
CY2017Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
295000 USD
CY2016Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
306000 USD
CY2017Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
205000 USD
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2000 USD
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
8000 USD
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8107000 USD
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8748000 USD
CY2016Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
57000 USD
CY2017Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
436000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
728000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
184000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
198000 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9088000 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
10166000 USD
CY2016Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0 USD
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0 USD
CY2016 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
180000 USD
CY2017 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
232000 USD
CY2016Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
15000 USD
CY2017Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
17000 USD
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-149.37
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.19
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3399663912
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.388
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.090
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.312
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.003
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.010
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.001
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.051
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.051
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
423000 USD
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
718000 USD
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2023000 USD
CY2017 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y5M0D
CY2016 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
67000 USD
CY2017 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-214000 USD
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3539000 USD
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7046000 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-16941000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-12039000 USD
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
6570000 USD
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1078000 USD
CY2016 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0 USD
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
3760000 USD
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5760000 USD
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-4093000 USD
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
43000 USD
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
-125000 USD
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
7000 USD
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-10000 USD
CY2016 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-860000 USD
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-610000 USD
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-126000 USD
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
195000 USD
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1548000 USD
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-811000 USD
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
9310000 USD
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-8276000 USD
CY2016 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-42000 USD
CY2017 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
2000 USD
CY2016 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
2000 USD
CY2017 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-3000 USD
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
244000 USD
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
509000 USD
CY2016 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-237000 USD
CY2017 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
13000 USD
CY2016 us-gaap Interest Expense
InterestExpense
724000 USD
CY2017 us-gaap Interest Expense
InterestExpense
795000 USD
CY2016 us-gaap Interest Paid
InterestPaid
478000 USD
CY2017 us-gaap Interest Paid
InterestPaid
611000 USD
CY2014Q1 us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P6Y
CY2016Q4 us-gaap Liabilities
Liabilities
18128000 USD
CY2017Q4 us-gaap Liabilities
Liabilities
9108000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20576000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28055000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12158000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3452000 USD
CY2016Q4 us-gaap Long Term Debt
LongTermDebt
5667000 USD
CY2017Q4 us-gaap Long Term Debt
LongTermDebt
4855000 USD
CY2016Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1213000 USD
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0 USD
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
4999000 USD
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4454000 USD
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4855000 USD
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6336000 USD
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26856000 USD
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-394000 USD
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-926000 USD
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5050000 USD
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19789000 USD
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-16941000 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-12039000 USD
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-779000 USD
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-604000 USD
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2017 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2016 us-gaap Operating Expenses
OperatingExpenses
17198000 USD
CY2017 us-gaap Operating Expenses
OperatingExpenses
21154000 USD
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-16162000 USD
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-11435000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1100000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
341000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
59000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
353000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
347000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
0 USD
CY2016 us-gaap Operating Leases Rent Expense Contingent Rentals
OperatingLeasesRentExpenseContingentRentals
266000 USD
CY2017 us-gaap Operating Leases Rent Expense Contingent Rentals
OperatingLeasesRentExpenseContingentRentals
281000 USD
CY2016 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
299000 USD
CY2017 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
332000 USD
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
613000 USD
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
565000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
114000 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
400000 USD
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
32000 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
32000 USD
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
281000 USD
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
278000 USD
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-55000 USD
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
191000 USD
CY2016 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
141000 USD
CY2017 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
394000 USD
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
926000 USD
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
403000 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
912000 USD
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
31513000 USD
CY2016 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
6000000 USD
CY2017 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
CY2016 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
450000 USD
CY2017 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0 USD
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
33000 USD
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
43000 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1120000 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2166000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
503000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1317000 USD
CY2016 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
CY2017 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1001000 USD
CY2016 us-gaap Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross
ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
0 USD
CY2017 us-gaap Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross
ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
1443000 USD
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13659000 USD
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14108000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-22604000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-34643000 USD
CY2016 us-gaap Revenue From Grants
RevenueFromGrants
346000 USD
CY2017 us-gaap Revenue From Grants
RevenueFromGrants
0 USD
CY2016 us-gaap Revenues
Revenues
1036000 USD
CY2017 us-gaap Revenues
Revenues
9719000 USD
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
682000 USD
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
1462000 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
4.21
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.836
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.831
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.792
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.808
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0224
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0217
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0101
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0197
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.799
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.810
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2361725 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.45
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
63000 USD
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
202000 USD
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
16135 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
657843 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.90
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.92
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3089352 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3672620 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.25
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.79
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
5177000 USD
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
9143000 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
5221000 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3596344 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.78
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.75
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.92
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.21
CY2017Q4 us-gaap Share Price
SharePrice
4.21
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3972000 USD
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y6M
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
58440 shares
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
444000 USD
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
27064000 USD
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
33000 USD
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
43000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
18230000 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
2448000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
18947000 USD
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 USD
CY2016Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
0 USD
CY2017Q4 xcur Common Stock Voting Rightsfor Each Share
CommonStockVotingRightsforEachShare
1 vote_per_share
CY2016Q4 xcur Common Stock Warrant Liability
CommonStockWarrantLiability
0 USD
CY2017Q4 xcur Common Stock Warrant Liability
CommonStockWarrantLiability
523000 USD
CY2017Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
13000 USD
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
113418 shares
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10119569 shares
CY2016Q4 xcur Accrued License Agreement Fees Current
AccruedLicenseAgreementFeesCurrent
1500000 USD
CY2017Q4 xcur Accrued License Agreement Fees Current
AccruedLicenseAgreementFeesCurrent
0 USD
CY2016 xcur Collaboration Agreement Revenue
CollaborationAgreementRevenue
690000 USD
CY2017 xcur Collaboration Agreement Revenue
CollaborationAgreementRevenue
9719000 USD
CY2016Q4 xcur Deferred Tax Liabilities Leasing Arrangements And Other
DeferredTaxLiabilitiesLeasingArrangementsAndOther
2000 USD
CY2017Q4 xcur Deferred Tax Liabilities Leasing Arrangements And Other
DeferredTaxLiabilitiesLeasingArrangementsAndOther
8000 USD
CY2017Q4 xcur Estimated Fair Valueof Common Stock Per Share
EstimatedFairValueofCommonStockPerShare
3.00
CY2017 xcur Fair Value Assumptions Impact Of10 Percent Change In Expected Volatility Rate
FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate
45000 USD
CY2017 xcur Fair Value Assumptions Impact Of10 Percent Change In Fair Value Of Common Stock
FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock
87000 USD
CY2016 xcur Issuance Of Common Stock Warrants
IssuanceOfCommonStockWarrants
0 USD
CY2017 xcur Issuance Of Common Stock Warrants
IssuanceOfCommonStockWarrants
536000 USD
CY2016 xcur Issuanceof Preferred Stock Warrants
IssuanceofPreferredStockWarrants
134000 USD
CY2017 xcur Issuanceof Preferred Stock Warrants
IssuanceofPreferredStockWarrants
0 USD
CY2016 xcur Payments Of Common Stock Financing Costs
PaymentsOfCommonStockFinancingCosts
0 USD
CY2017 xcur Payments Of Common Stock Financing Costs
PaymentsOfCommonStockFinancingCosts
3699000 USD
CY2016 xcur Payments Of Preferred Stock Financing Costs
PaymentsOfPreferredStockFinancingCosts
6000 USD
CY2017 xcur Payments Of Preferred Stock Financing Costs
PaymentsOfPreferredStockFinancingCosts
0 USD
xcur Paymentsfor License Agreements
PaymentsforLicenseAgreements
3419000 USD
CY2017 xcur Preferred Stock Liquidation Preference Percent Of Aggregate Cash Contributions
PreferredStockLiquidationPreferencePercentOfAggregateCashContributions
1.5
CY2016Q4 xcur Preferred Stock Warrant Liability
PreferredStockWarrantLiability
201000 USD
CY2017Q4 xcur Preferred Stock Warrant Liability
PreferredStockWarrantLiability
0 USD
CY2017Q3 xcur Price Based Anti Dilution Protection Gross Proceeds Threshold
PriceBasedAntiDilutionProtectionGrossProceedsThreshold
40000000 USD
CY2017Q4 xcur Retained Earnings Accumulated Deficit Inceptionto Date
RetainedEarningsAccumulatedDeficitInceptiontoDate
-53480000 USD
CY2017 xcur Share Conversion During Period Value In Connection With Merger
ShareConversionDuringPeriodValueInConnectionWithMerger
-31000 USD
CY2016 xcur Sharebased Compensation Arrangementby Sharebased Payment Award Fair Value Assumptions Forfeiture Rate
SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate
0.05
CY2017 xcur Sharebased Compensation Arrangementby Sharebased Payment Award Fair Value Assumptions Forfeiture Rate
SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate
0.05
CY2016 xcur Stock Issuance Costs Incurred During Noncashor Partial Noncash Transaction
StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction
0 USD
CY2017 xcur Stock Issuance Costs Incurred During Noncashor Partial Noncash Transaction
StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction
214000 USD
CY2017 xcur Tax Cuts And Jobs Act Of2017 Change In Tax Rate Deferred Tax Asset Income Tax Expense
TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense
3760000 USD
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. As of December 31, 2017 and 2016, the Company had cash and cash equivalents of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$25,764</font><font style="font-family:inherit;font-size:10pt;color:#000000;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$19,623</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, respectively. The cash balances at each respective period were maintained at two institutions. These deposits exceed federally insured limits.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company is currently not profitable and no assurance can be provided that it will ever be profitable. The Company&#8217;s research and development activities have required significant investment since inception and operations are expected to continue to require cash investment in excess of its revenues. See also Note 1, </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Description of Business and Basis of Presentation&#8212;Liquidity risk</font><font style="font-family:inherit;font-size:10pt;color:#000000;">, for more information.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The Company is subject to risks common in therapeutic development including, but not limited to, therapeutic candidates that appear promising in the early phases of development often fail because they prove to be inefficacious or unsafe, clinical trial results are unsuccessful, regulatory bodies may not approve the therapeutic or the therapeutic may not be economical in production or distribution. The Company is also subject to risks common to biotechnology firms including, but not limited to new and disruptive technological innovations, dependence on key personnel, protection of proprietary technology, the validity of and continued access to its owned and licensed intellectual property, limitations on the supply of critical materials, compliance with governmental regulations and market acceptance.</font></div></div>
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on certain assumptions which it believes are reasonable in the circumstance and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#8217;s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.</font></div></div>

Files In Submission

Name View Source Status
0001698530-18-000007-index-headers.html Edgar Link pending
0001698530-18-000007-index.html Edgar Link pending
0001698530-18-000007.txt Edgar Link pending
0001698530-18-000007-xbrl.zip Edgar Link pending
a20171128revisedpipeline.jpg Edgar Link pending
ast008breastcancer.jpg Edgar Link pending
ast008coloncancer.jpg Edgar Link pending
ast008lymphoma.jpg Edgar Link pending
ast008melanoma.jpg Edgar Link pending
ast5phase1results.jpg Edgar Link pending
exicure10-k2017.htm Edgar Link pending
exicure10k2017exhibit211.htm Edgar Link pending
exicure10k2017exhibit231.htm Edgar Link pending
exicure10k2017exhibit311.htm Edgar Link pending
exicure10k2017exhibit312.htm Edgar Link pending
exicure10k2017exhibit321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ibddata.jpg Edgar Link pending
ophthalmologyrabbiteyesdata.jpg Edgar Link pending
psoriasisskinmask.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
respiratoryactivitydata.jpg Edgar Link pending
Show.js Edgar Link pending
smafibroblastdata2.jpg Edgar Link pending
snatlrgraphica06.jpg Edgar Link pending
twosnasa04.jpg Edgar Link pending
xcur-20171231.xml Edgar Link completed
xcur-20171231.xsd Edgar Link pending
xcur-20171231_cal.xml Edgar Link unprocessable
xcur-20171231_def.xml Edgar Link unprocessable
xcur-20171231_lab.xml Edgar Link unprocessable
xcur-20171231_pre.xml Edgar Link unprocessable
xcur17preclinicalresults.jpg Edgar Link pending